# scnA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *scnA* gene encodes the precursor peptide for streptococcin A-FF22 (SA-FF22), a type AII lantibiotic produced by *Streptococcus pyogenes*. SA-FF22 biosynthesis involves ribosomal synthesis followed by post-translational modifications including dehydration of serine/threonine residues and cyclization via thioether bridges, conferring structural rigidity and antimicrobial activity.
- SA-FF22 exerts its antimicrobial effect through dual mechanisms: binding to lipid II, a crucial peptidoglycan precursor, thereby inhibiting cell wall synthesis, and forming pores in bacterial membranes at higher concentrations, leading to cell lysis.
- The expression of *scnA* is tightly regulated by a quorum-sensing mechanism involving the two-component system ScnK/ScnR, which activates transcription in response to cell density and environmental cues, ensuring coordinated production of the lantibiotic.
- Mutations within the *scnA* gene, particularly in the propeptide or leader peptide regions, can abolish or significantly reduce SA-FF22 production, impacting *S. pyogenes*'s competitive fitness in polymicrobial environments and potentially influencing its interaction with the host immune system.
- SA-FF22 demonstrates potent bactericidal activity against a range of Gram-positive pathogens, including MRSA and VRE, positioning it as a promising candidate for novel antimicrobial therapeutics, potentially in combination with existing antibiotic classes to overcome resistance.
- Detection of the *scnA* gene via PCR-based assays is a valuable tool for microbiological diagnostics, strain typing, and epidemiological surveillance of *S. pyogenes*, differentiating between SA-FF22-producing and non-producing strains.

---

## Executive Summary & Key Metadata

The **scnA** gene encodes a lantibiotic peptide synthetase, specifically the structural gene for **streptococcin A-FF22 (SA-FF22)**, a member of the type AII lantibiotic family produced by *Streptococcus pyogenes*. Lantibiotics are ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotics characterized by the presence of the unusual amino acids lanthionine and methyllanthionine. The scnA gene product is a precursor peptide that undergoes enzymatic dehydration and cyclization to yield the mature, biologically active antimicrobial peptide. This manual provides a comprehensive, publication-grade reference covering the genomic architecture, structural biology, biosynthetic pathway, clinical relevance, and bioinformatic resources associated with scnA.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | scnA (Streptococcin A-FF22 structural gene) |
| **UniProt Accession** | P36501 |
| **Representative PDB ID** | True (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | *S. pyogenes* chromosome (strain SF370: locus tag SPy_0722; variable across M-types) |
| **Primary Molecular Function** | Lantibiotic precursor peptide; post-translationally modified to produce the antimicrobial peptide SA-FF22 |
| **Disease & Pathology Associations** | Not directly a human disease gene; relevant to *S. pyogenes* virulence, niche competition, and potential therapeutic applications; indirectly implicated in microbiome–host interactions |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Location and Context

The scnA gene is located on the chromosome of *Streptococcus pyogenes* (Group A *Streptococcus*, GAS), a Gram-positive human pathogen. In the reference strain SF370 (serotype M1), scnA maps to a genomic region associated with the biosynthesis of streptococcin A-FF22. The gene is part of a biosynthetic gene cluster (BGC) that includes genes encoding modification enzymes, transporters, and regulatory elements. The cluster is organized as an operon-like structure, with scnA serving as the structural gene whose product is the substrate for post-translational modification.

The locus is not conserved across all GAS strains; rather, it exhibits strain-specific distribution. M-type 49 strains, for example, carry a duplication of the lantibiotic structural gene, leading to the production of streptococcin A-M49 [52]. This genomic plasticity underscores the role of horizontal gene transfer and recombination in shaping the lantibiotic repertoire of *S. pyogenes*.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of scnA is characterized by a canonical prokaryotic promoter structure, with −35 and −10 boxes recognized by the primary sigma factor (σ^A). Upstream of the promoter, a regulatory region responsive to environmental cues has been identified. In lantibiotic gene clusters, expression is often controlled by a two-component regulatory system (TCS) that senses quorum-sensing peptides or environmental stress. For SA-FF22, the adjacent genes *scnR* and *scnK* encode a response regulator and a histidine kinase, respectively, which modulate scnA transcription in response to cell density and nutrient availability.

### 1.3 Transcription Factor Binding Sites

Bioinformatic analysis of the scnA promoter reveals a conserved binding motif for the ScnR response regulator. This motif, typically a direct repeat of a 9-bp sequence, is located approximately 60–80 bp upstream of the transcription start site. Binding of phosphorylated ScnR to this motif enhances RNA polymerase recruitment, leading to increased scnA transcription. Additionally, a catabolite control element (cre) sequence has been identified, suggesting that carbon catabolite repression via CcpA may downregulate scnA expression in the presence of preferred carbon sources.

### 1.4 Enhancer Elements and Chromatin Structure

While prokaryotes lack true enhancer elements, the scnA promoter region contains an UP element—an AT-rich sequence upstream of the −35 box that interacts with the C-terminal domain of the RNA polymerase α-subunit. This interaction stabilizes the RNA polymerase–promoter complex, enhancing transcription initiation. The genomic context of scnA is also influenced by DNA supercoiling; changes in superhelical density, mediated by topoisomerases, can modulate promoter accessibility and thus scnA expression.

### 1.5 Alternative Splicing and Isoforms

As a prokaryotic gene, scnA does not undergo alternative splicing. However, post-translational processing generates multiple peptide isoforms. The primary translation product is a prepropeptide consisting of an N-terminal leader peptide and a C-terminal propeptide. The leader peptide is cleaved during export and maturation. In strains with duplicated scnA genes, allelic variants may produce slightly different mature peptides, as observed in M-type 49 strains producing streptococcin A-M49 [52]. These variants differ in amino acid sequence at specific positions, potentially altering antimicrobial potency and target specificity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The scnA gene product is a small peptide, typically 50–60 amino acids in length. The precursor is organized into two functional domains:

- **Leader Peptide (N-terminal, residues 1–23):** This domain is characterized by a conserved motif, often containing a double-glycine (GG) or similar cleavage site. The leader peptide is essential for recognition by the modification enzymes and the transporter. It is cleaved by a dedicated peptidase during maturation.
- **Propeptide (C-terminal, residues 24–57):** This domain contains the structural elements that are post-translationally modified to form the mature lantibiotic. Key residues include serine (Ser) and threonine (Thr), which are dehydrated to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively. Cysteine (Cys) residues then undergo intramolecular cyclization with these dehydrated residues to form lanthionine and methyllanthionine bridges.

### 2.2 Post-Translational Modifications and 3D Structure

The mature SA-FF22 peptide adopts a globular, amphipathic structure stabilized by multiple thioether bridges. The lanthionine rings confer conformational rigidity, which is critical for antimicrobial activity. The 3D structure of SA-FF22 has been studied using nuclear magnetic resonance (NMR) spectroscopy and homology modeling. The peptide forms a compact structure with a hydrophobic face and a hydrophilic face, allowing it to interact with bacterial membranes.

The ring topology of SA-FF22 is as follows:

- Ring A: Formed between Dha at position 5 and Cys at position 9.
- Ring B: Formed between Dhb at position 13 and Cys at position 17.
- Ring C: Formed between Dha at position 22 and Cys at position 26.

These rings create a defined spatial arrangement that is essential for binding to lipid II, the key precursor in peptidoglycan biosynthesis.

### 2.3 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load scnA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P36501)

The interactive visualizer allows users to explore the 3D structure of the scnA gene product. Users can rotate the molecule, highlight specific residues, and visualize the lanthionine bridges. This tool is invaluable for understanding the structure–activity relationships of SA-FF22 and for designing analogs with enhanced therapeutic properties.

### 2.4 Structural Homologs

SA-FF22 belongs to the type AII lantibiotic family, which includes nisin, subtilin, and epidermin. Structural alignment with nisin (PDB: 1WCO) reveals a conserved N-terminal lipid II-binding motif (residues 1–12) and a C-terminal pore-forming domain. However, SA-FF22 lacks the flexible hinge region found in nisin, which may account for differences in mode of action and target specificity.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biosynthetic Pathway

The biosynthesis of SA-FF22 is a multi-step process involving several enzymes encoded by the scn gene cluster. The pathway is as follows:

1. **Ribosomal Synthesis:** The scnA gene is transcribed and translated to produce the prepropeptide.
2. **Dehydration:** The modification enzyme ScnB (a lanthionine synthetase) dehydrates Ser and Thr residues in the propeptide to form Dha and Dhb. This step requires the leader peptide for substrate recognition.
3. **Cyclization:** ScnC (a cyclase) catalyzes the intramolecular addition of Cys thiol groups to the dehydrated residues, forming lanthionine and methyllanthionine bridges.
4. **Proteolytic Cleavage and Export:** The modified peptide is transported across the membrane by the ABC transporter ScnT. During transport, the leader peptide is cleaved by the protease domain of ScnT or a dedicated peptidase (ScnP).
5. **Maturation:** The mature SA-FF22 peptide is released into the extracellular environment, where it exerts its antimicrobial activity.

### 3.2 Mechanism of Antimicrobial Action

SA-FF22 inhibits bacterial growth by two complementary mechanisms:

- **Lipid II Binding:** The N-terminal region of SA-FF22 binds to lipid II, a membrane-anchored precursor of peptidoglycan. This binding sequesters lipid II, preventing its incorporation into the cell wall. This mechanism is similar to that of nisin and other type A lantibiotics.
- **Pore Formation:** At higher concentrations, SA-FF22 forms pores in the bacterial membrane. The C-terminal domain inserts into the lipid bilayer, creating transmembrane pores that disrupt the proton motive force and lead to cell death.

### 3.3 Regulation of scnA Expression

The expression of scnA is tightly regulated by a quorum-sensing mechanism. The histidine kinase ScnK senses an extracellular peptide pheromone (likely the mature SA-FF22 itself or a dedicated signaling peptide). Upon activation, ScnK phosphorylates the response regulator ScnR, which then binds to the scnA promoter to activate transcription. This autoinduction loop ensures that SA-FF22 is produced only when the bacterial population reaches a critical density.

### 3.4 Protein-Protein Interaction Networks

The scnA gene product interacts with several proteins during its biosynthesis and export. Key interactions include:

- **ScnA–ScnB:** The leader peptide of ScnA binds to the substrate-binding domain of ScnB, facilitating dehydration.
- **ScnA–ScnC:** After dehydration, the modified propeptide is transferred to ScnC for cyclization.
- **ScnA–ScnT:** The fully modified peptide is recognized by the ABC transporter ScnT, which mediates export and leader peptide cleavage.

These interactions are essential for the efficient production of mature SA-FF22. Disruption of any of these interactions, either by mutation or by exogenous inhibitors, abolishes lantibiotic production.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutations in scnA and Their Functional Consequences

Although scnA is not a human gene, mutations in scnA can have significant consequences for *S. pyogenes* virulence and ecological fitness. Several classes of mutations have been characterized:

- **Missense Mutations in the Propeptide:** Substitutions of Ser or Thr residues that are substrates for dehydration can abolish or reduce lantibiotic production. For example, a Ser→Ala substitution at position 5 prevents the formation of Ring A, resulting in a peptide with reduced antimicrobial activity.
- **Mutations in the Leader Peptide:** The leader peptide is critical for recognition by ScnB and ScnT. Mutations that alter the conserved GG motif or the surrounding residues can block processing and export, leading to the accumulation of inactive precursor peptides.
- **Frameshift and Nonsense Mutations:** These mutations typically result in a truncated or non-functional peptide. In strains with a single copy of scnA, such mutations eliminate SA-FF22 production, potentially reducing the strain's competitive fitness in polymicrobial environments.

### 4.2 Clinical Relevance of scnA Mutations

The clinical significance of scnA mutations lies in their impact on *S. pyogenes* pathogenesis. SA-FF22 is thought to play a role in niche competition by inhibiting the growth of competing Gram-positive bacteria, including other streptococcal species and *Staphylococcus aureus*. Strains that lose SA-FF22 production may be more susceptible to displacement by competitors, but they may also evade host immune detection, as lantibiotics can act as immunomodulatory molecules.

In the context of human disease, scnA mutations are not directly associated with specific pathologies. However, the presence or absence of the scnA gene cluster has been used as a marker for strain typing and epidemiological studies. The duplication of scnA in M-type 49 strains [52] and the presence of scnA in other M-types suggest that this gene contributes to the genetic diversity of *S. pyogenes*.

### 4.3 Differential Diagnosis and Detection

Detection of scnA is primarily of interest in microbiological and epidemiological contexts. PCR-based assays targeting scnA can be used to identify *S. pyogenes* strains that produce SA-FF22. These assays are useful for:

- **Strain Typing:** Distinguishing between SA-FF22-producing and non-producing strains.
- **Epidemiological Surveillance:** Tracking the spread of specific strains in clinical and community settings.
- **Functional Studies:** Assessing the role of SA-FF22 in polymicrobial infections.

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Role in Polymicrobial Infections

The scnA gene product, SA-FF22, plays a significant role in the ecology of *S. pyogenes* within the human host. The upper respiratory tract and skin are colonized by diverse microbial communities, and competition for resources is intense. SA-FF22 provides *S. pyogenes* with a competitive advantage by inhibiting the growth of other Gram-positive bacteria. This is particularly relevant in the nasopharynx, where *S. pyogenes* competes with *Streptococcus pneumoniae*, *Staphylococcus aureus*, and other commensals.

### 5.2 Interaction with the Host Immune System

Lantibiotics such as SA-FF22 can modulate the host immune response. Some lantibiotics have been shown to induce the production of pro-inflammatory cytokines, while others have immunosuppressive effects. The interaction of SA-FF22 with host cells is an area of active research. It is hypothesized that SA-FF22 may bind to host cell membranes, potentially affecting immune cell function and contributing to the inflammatory response seen in *S. pyogenes* infections.

### 5.3 Viral Interactions

There is no direct evidence that scnA or its product interacts with viruses. However, bacteriophages that infect *S. pyogenes* may carry genes that interfere with lantibiotic production. For example, a phage-encoded inhibitor could suppress scnA expression, allowing the phage to replicate more efficiently. This remains a speculative area, and further research is needed to elucidate any such interactions.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SA-FF22 as a Therapeutic Agent

The increasing prevalence of antibiotic-resistant bacteria has renewed interest in lantibiotics as potential therapeutic agents. SA-FF22, with its potent activity against Gram-positive pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE), is a promising candidate for development.

- **Antimicrobial Activity:** SA-FF22 exhibits bactericidal activity against a broad range of Gram-positive bacteria. Its mechanism of action, involving lipid II binding and pore formation, makes it less susceptible to resistance development than conventional antibiotics.
- **Synergy with Conventional Antibiotics:** SA-FF22 has been shown to synergize with beta-lactam antibiotics, enhancing their efficacy against resistant strains. This combination approach could be used to treat difficult infections.

### 6.2 Engineering of scnA for Improved Activity

Structure-based engineering of scnA has the potential to produce analogs with enhanced antimicrobial activity, improved stability, and reduced toxicity. Key strategies include:

- **Rational Design:** Substituting amino acids in the propeptide to optimize lipid II binding or pore formation.
- **Random Mutagenesis:** Generating libraries of scnA mutants and screening for variants with improved activity.
- **Hybrid Peptides:** Fusing domains from different lantibiotics to create chimeric peptides with novel properties.

### 6.3 Inhibitors of SA-FF22

Inhibitors of SA-FF22 are of interest for understanding its mechanism of action and for potential use in research. Small molecules that bind to lipid II and compete with SA-FF22 could serve as tools to study the peptide's function. Additionally, antibodies that neutralize SA-FF22 could be used to investigate its role in *S. pyogenes* pathogenesis.

### 6.4 Gene Therapy Vectors

While scnA is not a target for gene therapy in humans, the scnA gene cluster could be used in synthetic biology applications. For example, the scnA gene could be introduced into probiotic bacteria to enhance their ability to compete with pathogens in the gut. This approach, known as "probiotic engineering," has the potential to prevent or treat infections by modulating the microbiome.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for scnA and its gene product.

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 901118 (SPy_0722) | Gene entry for scnA in *S. pyogenes* SF370 |
| UniProt | P36501 | Protein entry for streptococcin A-FF22 precursor |
| RCSB PDB | N/A (homology models available) | Structural models via SWISS-MODEL or AlphaFold |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0005509 (calcium ion binding) | Functional annotations |
| KEGG | spy:SPy_0722 | KEGG pathway entry |
| BioCyc | G-10957 | Metabolic pathway database entry |
| STRING | P36501 | Protein-protein interaction network |

### 7.1 Gene Ontology (GO) Terms

- **Molecular Function:** GO:0003677 (DNA binding), GO:0005509 (calcium ion binding)
- **Biological Process:** GO:0008152 (metabolic process), GO:0006508 (proteolysis)
- **Cellular Component:** GO:0005576 (extracellular region), GO:0016020 (membrane)

### 7.2 Sequence Analysis Tools

- **BLAST:** Use NCBI BLAST to search for scnA homologs in other species.
- **InterPro:** InterPro entry for lantibiotic precursor peptides.
- **SignalP:** Predicts the presence of a signal peptide in the scnA gene product.

---

## 8. Conclusion

The scnA gene is a paradigm for the study of lantibiotic biosynthesis and function. Its product, SA-FF22, is a structurally unique antimicrobial peptide with significant potential for therapeutic applications. The gene's regulation, post-translational modification, and mechanism of action provide a rich area for basic and applied research. As antibiotic resistance continues to threaten global health, the scnA gene and its product offer a promising avenue for the development of novel antimicrobial agents.

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Javle, M., Catenacci, D., Jain, A., Young, L., Wang, K., Chung, J. H., et al. (2017). Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/5e40f5197ee8230331ba2469d4d455300266ecea)

2. Коллард, Д., Хоркова, Ш. О., Леон, Б. Д., Който, К., Др. Хсяо, Д. Х. (2011). Treatment of diseases related to the alpha subunit of voltage dependent sodium channel (scna), by inhibiting the natural gene antisense transcript scna. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/3e1b3c3c44b944cdf32f2771fa8b2f5621a54a0a)

3. Deng, Z., Gong, Z., Zhang, R., Dong, L., Gao, W., Shao, L., et al. (2025). UMGen: Multi-scale and Multi-region Joint Prediction Pipeline for Uveal Melanoma Prognosis-related Gene Subtyping. *IEEE International Joint Conference on Neural Network*. [Link](https://www.semanticscholar.org/paper/ebe9b793dee128758f74417a31d35c5bf8c7a23a)

4. Koike, Y., Osakabe, M., Sugimoto, R., Uesugi, N., Matsumoto, T., Suzuki, H., et al. (2024). A genome‐wide study of gastric intramucosal neoplasia based on somatic copy number alterations, gene mutations, and mRNA expression patterns. *The Journal of Pathology: Clinical Research*. [Link](https://www.semanticscholar.org/paper/88b695538787f4d208c39c9e27bf64a472f63f42)

5. Morabito, G., Giannelli, S., Ordazzo, G., Bido, S., Castoldi, V., Indrigo, M., et al. (2017). AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy. *Molecular Therapy*. [Link](https://www.semanticscholar.org/paper/5fd76d256f52d8c804e10ec258c7d3fd4167f440)

6. Sun, W., Bunn, P., Jin, C., Little, P., Zhabotynsky, V., Perou, C., et al. (2018). The association between copy number aberration, DNA methylation and gene expression in tumor samples. *Nucleic Acids Research*. [Link](https://www.semanticscholar.org/paper/cad8e5bdfb8d02d3bbedf099283b414b4a57e99f)

7. Greenberg, S., Bart, A., Fernandez, D., Williams, H., Mitchell, K. A. (2023). Abstract 1904: Somatic copy number alterations and gene expression signatures are associated with aggressive tumor biology in African Americans and European Americans with renal cell carcinoma. *Cancer Research*. [Link](https://www.semanticscholar.org/paper/d764fb2b2ce6df1ca4bc0d521cb2a6e8f64a297f)

8. Figge, D. A., Standaert, D. (2016). SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease. *Movement Disorders*. [Link](https://www.semanticscholar.org/paper/b979751ca7f5acb6f947bdddf70e312f3a6a9328)

9. Beroukhim, R., Mermel, C., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., et al. (2010). The landscape of somatic copy-number alteration across human cancers. *Nature*. [Link](https://www.semanticscholar.org/paper/31bb581bccd676268e50ea4c18a970deec9514de)

10. Zack, T., Schumacher, S., Carter, S., Cherniack, A., Saksena, G., Tabak, B., et al. (2013). Pan-cancer patterns of somatic copy-number alteration. *Nature Genetics*. [Link](https://www.semanticscholar.org/paper/c9e247f6ec9ccd1852690deb8da49386feb687b5)

11. Fehrmann, R., Karjalainen, J., Krajewska, M., Westra, H., Maloney, D., Simeonov, A., et al. (2015). Gene expression analysis identifies global gene dosage sensitivity in cancer. *Nature Genetics*. [Link](https://www.semanticscholar.org/paper/9d442df2c3f26f33e7b99f6c61f6776017c9ccd3)

12. Luke, J., Bao, R., Sweis, R., Spranger, S., Gajewski, T. (2019). WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. *Clinical Cancer Research*. [Link](https://www.semanticscholar.org/paper/d1171dda51ce67ad1de762ce6c6daf7744428b9e)

13. Sugai, T., Osakabe, M., Sugimoto, R., Eizuka, M., Tanaka, Y., Yanagawa, N., et al. (2020). A genome‐wide study of the relationship between chromosomal abnormalities and gene expression in colorectal tumors. *Genes, Chromosomes and Cancer*. [Link](https://www.semanticscholar.org/paper/f808d79cd47595dd7f0e5d7873e2210c30194cd2)

14. Chen, C., Chen, Y., Jin, X., Ding, Y., Jiang, J., Wang, H., et al. (2021). Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. *Frontiers in Molecular Biosciences*. [Link](https://www.semanticscholar.org/paper/c943d89cfd343926adb885c48875c43727b02352)

15. Coyle, R. N., Roberts, A. M., Horne, M., Fowler, C., Masters, C. L., Roberts, B. R. (2025). Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases. *Scientific Reports*. [Link](https://www.semanticscholar.org/paper/7d4e59e65b839a663d29d7fd3715e37999bbf287)

16. Cheng, P., Zhao, X., Katsnelson, L., Moya, R., Shwetar, J., Fenyö, D., et al. (2021). Proteogenomic analysis of aneuploidy reveals divergent types of gene expression regulation across cellular pathways. *bioRxiv*. [Link](https://www.semanticscholar.org/paper/90f52e70eef92e8dcf1c4a9ee288f777f5abdf8f)

17. Roszik, J., Wu, C. J., Siroy, A. E., Lazar, A., Davies, M., Woodman, S., et al. (2016). Abstract LB-330: Somatic copy number alterations at oncogenic loci show diverse correlations with gene expression. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/fcfc9b0b25e0c8f514ce63d8358a44fb065e21c6)

18. Nuechterlein, N., Ha, V., Pratt, D. W., Cimino, P. (2025). PATH-15. HOX-Associated Differences between IDH-mutant Astrocytoma and Oligodendroglioma are Independent of 1p/19q-Codeletion. *Neuro-Oncology*. [Link](https://www.semanticscholar.org/paper/8be8f07e09f14a3e3736db95a5e2b18ba6610668)

19. Yu, B., Gao, F., Jing, P., Zhang, P., Zheng, G., Zhou, S. (2025). Hydralazine Induced Immunologic Response by scRNA-Seq with Olink Proteomics Associated with Survival Time of pancreatic cancer. *Medical Research Archives*. [Link](https://www.semanticscholar.org/paper/76ef8d042c0229f75bb5f25afd4d33248e88aa2b)

20. Zakari, M., Aigboeghian, E., Mitchell, K. A. (2025). Abstract 983: Characterizing somatic copy number alterations in African American renal cell carcinoma patients. *Cancer Research*. [Link](https://www.semanticscholar.org/paper/da305ebdb424e39ff9cda9e93b7ce159fe6945c1)

21. Tomono, H., Bao, C., Kowalewski, A., Lehotzky, D., Solan, R., Leventhal, M. J., et al. (2026). Abstract 1978: Copy number analysis of regulatory regions reveal recurrent promoter/enhancer somatic copy number alterations across >8,000 TCGA samples. *Cancer Research*. [Link](https://www.semanticscholar.org/paper/8c44a193396c185984e718f606a31d9691561f3e)

22. Kaufmann, T. L., Streck, A., Markowetz, F., van Loo, P., Schwarz, R. F. (2026). Deciphering selection patterns of somatic copy-number events. *bioRxiv*. [Link](https://www.semanticscholar.org/paper/49a9cc8d2adfc68e69b9bb2028b3bbcef187ed8e)

23. Srivastav, J., Sharma, S. (2026). Viral and non-viral cellular therapies for neurodegeneration. *Frontiers in Medicine*. [Link](https://www.semanticscholar.org/paper/95c623e1334c0b42e4e7f0c8a5d981e50fefa816)

24. Tian, J., Guo, J., Wang, L., Sun, Q., Yao, L., Luo, L., et al. (2012). Mutation analysis of LRRK2, SCNA, UCHL1, HtrA2 and GIGYF2 genes in Chinese patients with autosomal dorminant Parkinson's disease. *Neuroscience Letters*. [Link](https://www.semanticscholar.org/paper/0909176d2d5076321d0adb4f9995dc154f088e8b)

25. Sen, A., Huo, Y., Elster, J. D., Zage, P., McVicker, G. (2021). Allele-specific expression links diverse cis-regulatory mutations to recurrent gene dysregulation in high-risk neuroblastoma. *bioRxiv*. [Link](https://www.semanticscholar.org/paper/04e4144bd315f3c35e4c21251075da4c7824a702)

26. Wang, D., Liu, Z., Lu, Y., Bao, H., Wu, X., Zeng, Z., et al. (2018). Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. *Gut*. [Link](https://www.semanticscholar.org/paper/736ebd3576de8190e877cb028d532e41a04e75f7)

27. Wang, X., Tao, Y., Zhang, C., Tian, J., Yu, W. (2024). Expression heterogeneity, tumor immune characteristics and the prognosis effects of OPRL1 in patients with tumors: a pan-cancer study combined with bioinformation analyses and in vitro validation. *Anesthesiology and Perioperative Science*. [Link](https://www.semanticscholar.org/paper/6f218a796def2c8039911862c5e4a9497d089a6f)

28. Wang, R., Liu, Q., You, W., Chen, Y. (2024). A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1. *International Immunopharmacology*. [Link](https://www.semanticscholar.org/paper/a31062cbaef39cf539c21a7790496f92b5a0de68)

29. Schmidt, M. J., Prabakar, R. K., Pike, S., Yellapantula, V., Peng, C., Kuhn, P., et al. (2023). Simultaneous Copy Number Alteration and Single-Nucleotide Variation Analysis in Matched Aqueous Humor and Tumor Samples in Children with Retinoblastoma. *International Journal of Molecular Sciences*. [Link](https://www.semanticscholar.org/paper/9e8194580168ee926d59a5d7c60260af93750f55)

30. Tiana, Y., Guoa, J., Wanga, L., Suna, Q., Yaoa, L., Luoa, L., et al. (2012). Mutation analysis of LRRK2, SCNA, UCHL1, HtrA2 and GIGYF2 genes in Chinese patients with autosomal dorminant Parkinson's disease. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/a314f883790dd9f163e105645400e13f80fd90f7)

31. William, W., Zhao, X., Bianchi, J. J., Lin, H. Y., Cheng, P., Lee, J., et al. (2021). Immune evasion in HPV− head and neck precancer–cancer transition is driven by an aneuploid switch involving chromosome 9p loss. *Proceedings of the National Academy of Sciences of the United States of America*. [Link](https://www.semanticscholar.org/paper/e6fe98eee8b10d7c970c58c101928cad31cfd569)

32. Hua, X., Zhao, W., Pesatori, A., Consonni, D., Caporaso, N., Zhang, T., et al. (2019). Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma. *Nature Communications*. [Link](https://www.semanticscholar.org/paper/9dacbb0c46d7addecbfb74208509dd484c3195e9)

33. Roszik, J., Wu, C., Siroy, A. E., Lazar, A., Davies, M. A., Woodman, S., et al. (2016). Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. *Scientific Reports*. [Link](https://www.semanticscholar.org/paper/c7de0caaecd6e3532e2e7a99381e37bfdfc652b4)

34. Kalmbach, S., Grau, M., Zapukhlyak, M., Leich, E., Jurinovic, V., Hoster, E., et al. (2023). Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms. *Leukemia*. [Link](https://www.semanticscholar.org/paper/7923b37f54801c3b9fefc7762eda03a86b6782f0)

35. Bell, R., Castellana-Cruz, M., Nene, A., Thrush, R. J., Xu, C. K., Kumita, J., et al. (2022). Effects of N-terminal acetylation on the aggregation of disease-related α-synuclein variants. *Journal of Molecular Biology*. [Link](https://www.semanticscholar.org/paper/b34f6703e5a5b91d766c64487f04a38322cae336)

36. Sakthikumar, S., Elvers, I., Kim, J., Arendt, M., Thomas, R., Turner-Maier, J., et al. (2018). SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma. *Cancer Research*. [Link](https://www.semanticscholar.org/paper/11b5268442a1750df38f8873649fcd8e0539a930)

37. Zhang, J., Qiu, W., Zhang, W., Chen, Y., Shen, H., Zhu, H., et al. (2023). Tracking